Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-03-01
2005-03-01
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S211150, C540S544000
Reexamination Certificate
active
06861419
ABSTRACT:
The present invention is directed to substituted 1,4-thiazepine and analogs thereof, represented by the general Formula I:wherein the dashed lines, A1, A2, A3, X1and R1are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of capases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
REFERENCES:
patent: WO 9620721 (1996-07-01), None
patent: WO 9856785 (1998-12-01), None
patent: WO 9918856 (1999-04-01), None
patent: WO 9956736 (1999-11-01), None
patent: WO 0004901 (2000-02-01), None
patent: WO 0007017 (2000-02-01), None
Vaux et al., Cell Death in Development, Cell, Jan. 22, 1999, vol. 96, pp. 245-254, especially 248.*
Balasubramanian et al., Recent Developments in Cancer Cytotoxics, Annual Reports in Medicinal Chemistry, vol. 33, pp. 151-159, 1996.*
Draetta et al., Cell Cycle Control and Cancer, Annual Reports in Medicinal Chemistry, vol. 31, pp. 241-248, 1996.*
Salmon et al., Principles of Cancer Therapy, Cecil Textbook of Medicine, 20th ED., vol. 1, pp. 1036-1049, 1996.*
CAPLUS printout for WO 00/07017, Feb. 10, 2000.*
Attia, A.E-H., and Michael, M., “Azachalcones. IV+. Reactions of Azachalcones with O-Phenylenediamine,”Gazz. Chim. Ital. 112:387-390, Wiley-VCH Verlag GmbH (1982).
Barot, V.M., et al., “New 7-(2'-Hydroxy-4' Methoxy-5'-Bromophenyl)-5-Substituted Phenyl-2,3,6,7 Tetrahydro-1, 4-Oxazapine,”J. Inst. Chemists(India) 71:70-71, Calcutta: The Institution (1999).
Batteux, F., et al., “Gene Therapy of Experimental Autoimmune Thyroiditis by In Vivo Administration of Plasmid DNA Coding for Fas Ligand,”J. Immunol. 162:603-608, American Association of Immunologists (Jan. 1999).
Bharucha, P.B. and Naik, H.B., “Synthesis and Antibacterial Activity of Some Chalcones and 1,4-Oxazipine Derivatives,”Asian J. Chem. 12:318-320, M.R.S. Pushpa Agarwal (Jan.-Mar. 2000).
Boirivant, M., et al., “Lamina Propria T Cells in Crohn's Disease and Other Gastrointestinal Inflammation Show Defective CD2 Pathway-Induced Apoptosis,”Gastrointerology116:557-565, WB Saunders Company (Mar. 1999).
Coven, T.R., et al., “PUVA-induced lymphocyte apoptosis: Mechanism of action in psoriasis,”Photodermatol. Photoimmunol. Photomed. 15:22-27, Munksgaard (Feb. 1999).
Curtze, J. and Thomas, K., “RingschluBreaktionen an heterocyclischen Sechs- und Siebenringsystemen,”Liebigs Ann. Chem. 328-333, Verlag Chemie (1974).
de Sarro, G., et al., “5H-[1,2,4]Oxadiazolo[5,4-d] [1,5]benzothiazepines as anticonvulsant agents in DBA/2 mice,”Eur. J. Med. Chem. 30:925-929, Elsevier Science (1995).
Djudjić, R. and Trkovnik, M., “Syntheses of new Coumarinic Benzothiazepines, Benzodiazepines, and Benzopyranodiazepines,”Croatica Chemica Acta63:13-18, Nolit Publishing House (1990).
Ellis, R.E., and Horvitz, H.R., “TwoC. elegansgenes control the programmed deaths of specific cells in the pharynx,”Development112:591-603, Company of Biologists, Ltd. (1991).
Ellis R.E., et al., “Mechanisms and Functions of Cell Death,”Annu. Rev. Cell Biol. 7:663-698, Annual Reviews, Inc. (1991).
Fodili, M., et al., “An Efficient Synthesis of New 2-Pyronyl-1,5-Benzodiazepine Derivatives,”Synthsis 5:811-814, Thieme Stuttgart (May 1999).
Friesen, C., et al., Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells,Nat. Med. 2:574-577, Nature America, Inc. (1996).
Glücksmann, A., “Cell deaths in normal vertebrate ontogeny,”Biol. Rev. Camb. Philos. Soc. 26:59-86, Cambridge University Press (1951).
Glücksmann, A., “Cell death in normal development,”Arch Biol(Liège) 76:419-437, Vaillant Germanne SA (1965).
Gupta, A.K., et al., “Syntheses & Spectral Studies of Some 2-(Substituted phenyl)-4-phenyl-1,5-benzothiazepines,”Indian J. Chem. 22B:1057-1059, Publications and Information Directorate (CSIR) (1983).
Heenen, M., et al., “Methotrexate induces apoptotic cell death in human keratonicytes,”Arch. Dermatol. Res. 290:240-245, Springer-Verlage (1998).
Ibrahim, S.S., et al., “Synthesis of New 3-Acryloyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxoquinoline. Derivatives and their Behavior towards Some Nucleophiles,”Chem. Papers51:33-42, Slovak Academic Press, Ltd. (1997).
Ibrahim, S.S., et al., “New Quinolones and Naphthyridinones Bearing Heterocyclic Rings,”Chem. Papers53:53-64, Slovak Academic Press, Ltd. (Jan./Feb. 1999).
Infante, A.J., et al., “The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis,”J. Pediatr. 133:629-633, Mosby, Inc. (1998).
Jadhav, K.P. and Ingle, D.B., “Synthesis of 2,4-Diaryl-2,3-dihydro-1,5-benzothiazepines and Their 1,1-Dioxides as Antibacterial Agents,”Indian J. Chem. 22B:180-182, Publications & Information Directorate(CSIR) (1983).
Khanna, M.S., et al., “A novel approach to tetrahysrobenzothiazepines from chalcones using o-aminothiophenol,”Indian J. of Chem. 34B:333-335, Publications and Information Directorate (CSIR) (1995).
Lévai, A. and Bognár, R., “Oxazepines and Thiazepines, II. Synthesis of 2,3-Dihydro-2,4-Diphenyl-1,5-Benzothiazepines by the Reaction of 2-Aminothiophenol with Chalcones Substituted in Ring B,”Acta Chim.(Budapest) 88:293-300, Budapest: Akademiai Kiado (1976).
Lévai, A., “Oxazepines and Thiazepines 38* Synthesis of 2,4-Diaryl-2,3-Dihydro-1,5-Benzothiazepines by the Reaction od 2-Hydropxychalcones with 2-Aminothiophenol,”Heterocyclic Comm. 5:359-364, Freund Publishing (1999).
Lévai, A., “Synthesis and Chemical Transformation of 1,5-Benzothiazepines,”J. Heterocyclic Chem. 37:199-214, Hetero Corporation (Mar.-Apr. 2000).
López-Hoyos, M., et al., “Regulation of B cell apoptosis by Bcl-2 and Bcl-XLand its role in the development of autoimmune disease (Review),”Int. J. Mol. Med. 1:475-483, Professor DA Spandidos (1998).
Los, M., et al., Cross-Resistance of CD95—and Drug-Induced Apoptosis as a Consequence of Deficient Activation of Caspases (ICE/Ced-3 Proteases)Blood90:3118-3129, American Society of Hematology (1997).
Mohamed, H.A., et al., “Synthesis of 3-Heteroaryl-4-hydroxybenzocarbostyrils,”J. Indian Chem. Soc. 69:82-84, Calcutta: The Society (1992).
Naik, V.R. and Naik, H.B., “Synthesis and Antibacterial Activity of 2,3-Dihydro-4-(2′-Hydroxy-3′-Bromo-5′-Ethylphen-1′-yl)-2-Substitutedphenyl-1,5-Benzothiazepine Derivatives,”Asian J. Chem. 11:661-662, M.R.S. Pushpa Agarwal (Apr.-Jun. 1999).
Ohsako, S., and Elkon, K.B., “Apoptosis in the effector phase of autoimmune diabetes, multiple sclerosis and thyroiditis,”Cell Death Differ. 6:13-21, Stockton Press (Jan. 1999).
Ohta, S., et al., “Inhibition of P-selectin specific cell adhesion by a low molecular weight, non-carbohydrate compound, KF38789,”Inflamm. Res. 50:544-551, Birkhäuser Verlag, Basel (Nov. 2001).
O'Reilly, L.A., and Strasser, A., “Apoptosis and autoimmune disease,”Inflamm. Res. 48:5-21, Birkhäuser Verlag AG (Jan. 1999).
Orlov, V.D., et al., “2,4-Diaryl-2,3-Dihydrobenzo[b][1,4]Thiazepines,”Translation from Khim. Getero. Soed. 12:1638-1642, Plenum Publishing Corp. (1983).
Orrenius, S., “Apoptosis: molecular mechanisms and implications for human disease,”J. Intern. Med. 237:529-536, Blackwell Science, Ltd. (1995).
Ozawa, M., et al., “312-nanometer Ultraviolet B Light (Narrow-Band UVB) Induces Apoptosis of T Cells within Psoriatic Lesions,”J. Exp. Med. 189:711-718, Rockefeller University Press (Feb. 1999).
Savill, J., “Apoptosis in r
Cai Sui Xiong
Drewe John A.
Litvak Joane
Sendzik Martin
Shelton Emma Jane
Coleman Brenda
Cytovia, Inc.
LandOfFree
Substituted 1, 4-thiazepine and analogs as activators of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 1, 4-thiazepine and analogs as activators of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 1, 4-thiazepine and analogs as activators of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3448153